🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CAR T cell #cancer #immunotherapy may demonstrate more efficacy when CD4 and CD8 CAR T cells – each with complementary roles – work together with the patient’s immune system to eliminate tumors, suggests a new Science Immunology study in mice: fcld.ly/wewzc8z

Great review by a talented graduate student in our lab Joel Rurik @DevBioAcademic. Immunomodulation and immunotherapy hold great promise for the future of cardiac therapeutics and regenerative medicine.

Our work “A transcriptional switch governs fibroblast activation in heart disease” previously on bioRxiv is now online nature. A great team effort Gladstone Institutes Deepak Srivastava and all the fantastic collaborators. A new thread /1 👇 nature.com/articles/s4158…

Maybe this hidden gem is not so hidden anymore...

Well deserved.

#CARTCell Principal Scientist #hiring at Capstan Therapeutics- responsible for setting up and executing on a robust preclinical CAR T program with applications in multiple disease categories, cell types, and indications. lnkd.in/eyH-Mn7v

An experimental #mRNA therapy makes CAR-T cells inside the body to target heart fibrosis. The Penn Medicine study marks an important step in developing accessible and affordable "off-the-shelf" personalized immunotherapies. fiercebiotech.com/research/mrna-…

JUST OUT: New, off-the-shelf method for generating CAR T cells in vivo developed and tested in mice. bit.ly/3q1KfMe

In this week's Science Magazine cover story, @DevBioAcademic, Haig Aghajanian, The Drew Weissman Lab, Parhiz, Jon Epstein Lab, & al. use CD5-targeted lipid #nanoparticles to generate therapeutic #CARTcells in vivo! bit.ly/Sci_abm0594 w/ PS by Gao & Chen: bit.ly/Sci_abn0851

Researchers @DevBioAcademic Haig Aghajanian The Drew Weissman Lab @jonepstein1 and team harnessed #mRNA tech to create therapeutic CAR-T cells (in mice) to treat heart disease. mRNA shot spawns CAR-T cells in the body to repair heart disease damage | FierceBiotech bit.ly/3fVWpQP

🚨New: Decade-long #leukemia remissions with persistence of CD4+ CAR T-cells demonstrates long-term potential and clonal stability of #CARTCell therapy #tcell #tcellrx #cancer #immunotherapy Penn Medicine nature Portfolio nature.com/articles/s4158…

🆕Review: CAR-based therapies: opportunities for immuno-medicine beyond cancer- by Haig Aghajanian, @DevBioAcademic, @jonepstein1 #immunotherapy Nature Metabolism nature.com/articles/s4225…

Merging RNA technology and #cardioimmunology to tackle heart fibrosis - some thoughts from McKinsey Lab and us on this exciting new approach by Jon Epstein Lab & colleagues. Check out the full paper at science.org/doi/10.1126/sc… #CardioTwitter

We are excited to announce 3 new speakers at our LNP-RNA Therapeutics Beyond COVID Virtual Symposium! Meet Philip Robert from CPI, Adrian Abbotts from Siemens & Haig Aghajanian from Penn Click here to register for the 2-Day virtual event: ow.ly/a5U950Ik76P

PERSPECTIVE | Aghajanian, Rurik & Jon Epstein Lab (Penn Medicine) summarize the ongoing development of CAR-based therapies for indications beyond cancer, including for cardiometabolic diseases, fibrosis, autoimmune diseases & aging. #immunotherapy nature.com/articles/s4225…

NEJM Fighting Cardiac Fibrosis with CAR T Cells- Clinical Implications of Basic Research "An advance for several reasons" 1) off the shelf CAR T cells 2) transient expression 3) remarkable lipid nanoparticle safety record Penn Medicine The Drew Weissman Lab ⁦ Jon Epstein Lab Carl June

“CAR-T made entirely within the body” Lots of good work ahead to make this a reality! Capstan Therapeutics Laura Shawver Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 Haig Aghajanian lnkd.in/eQpteQZD

🏆 Best of #NatMetab2022 | CITATIONS #14 The Jon Epstein Lab (Penn Medicine) summarize ongoing developments of CAR-based therapies for indications beyond #cancer, including for cardiometabolic diseases, fibrosis, autoimmune diseases & aging. nature.com/articles/s4225…

In Science, researchers present a new method to safely and preferentially generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA directly to T cells. The approach showed rapid and sustained immune reprogramming in preclinical models,